In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea
Molecular Pharmaceutics · 03.07.2023 · 20 (7) · 3298-3319
DOI: 10.1021/acs.molpharmaceut.3c00195 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.06.2023. Verfasst von Inès De Hoon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, F-59000 Lille, France. Hauptthemen laut MEDLINE: Cornea, Cell Culture Techniques. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 163 Literaturangaben. Gefördert von: Universit? de Lille, Agence Nationale de la Recherche, H2020 Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
Drug permeation across the cornea remains a major challenge due to its unique and complex anatomy and physiology. Static barriers such as the different layers of the cornea, as well as dynamic aspects such as the constant renewal of the tear film and the presence of the mucin layer together with efflux pumps, all present unique challenges for effective ophthalmic drug delivery. To overcome some of the current ophthalmic drug limitations, the identification and testing of novel drug formulations such as liposomes, nanoemulsions, and nanoparticles began to be considered and widely explored. In the early stages of corneal drug development reliable in vitro and ex vivo alternatives, are required, to be in line with the principles of the 3Rs (Replacement, Reduction, and Refinement), with such methods being in addition faster and more ethical alternatives to in vivo studies. The ocular field remains limited to a handful of predictive models for ophthalmic drug permeation. In vitro cell culture models are increasingly used when it comes to transcorneal permeation studies. Ex vivo models using excised animal tissue such as porcine eyes are the model of choice to study corneal permeation and promising advancements have been reported over the years. Interspecies characteristics must be considered in detail when using such models. This review updates the current knowledge about in vitro and ex vivo corneal permeability models and evaluates their advantages and limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, F-59000 Lille, France.
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
ORCID-Profile: Rabah Boukherroub, Stefaan C De Smedt, Sabine Szunerits, Félix Sauvage
Förderung
- Universit? de Lille
- Agence Nationale de la Recherche
- H2020 Marie Sklodowska-Curie Actions
- Centre National de la Recherche Scientifique
- Renatech network
Zitieren
APA
De Hoon, I., Boukherroub, R., De Smedt, S. C., Szunerits, S., & Sauvage, F. (2023). In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea. Molecular Pharmaceutics, 20(7), 3298-3319. https://doi.org/10.1021/acs.molpharmaceut.3c00195
Vancouver
De Hoon I, Boukherroub R, De Smedt SC, Szunerits S, Sauvage F. In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea. Molecular Pharmaceutics. 2023;20(7):3298-3319. doi:10.1021/acs.molpharmaceut.3c00195
BibTeX
@article{DeHoon2023,
author = {De Hoon, Inès and Boukherroub, Rabah and De Smedt, Stefaan C and Szunerits, Sabine and Sauvage, Félix},
title = {In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {7},
pages = {3298--3319},
doi = {10.1021/acs.molpharmaceut.3c00195}
}
EUVIMED